Novel ADCs May Be a Very Successful and Useful Drug for the Treatment of Ovarian Cancer

In the treatment of ovarian cancer, three antibody drug conjugates (ADCs) are approved. This gives an opportunity for a greater precision against the cancer cells – but at the same time the clinicians also must face both known and novel toxicities according to the treatment. At Onkologisk Forum 2025, Professor Gottfried Konecny gives a review of his recent experiences in the development of novel antibody-drug conjugates, which may be a very successful and useful drug for the treatment of ovarian cancer.